The preoperative neutrophil-lymphocyte ratio predicts recurrence and survival among patients undergoing R0 resections of adenocarcinomas of the esophagogastric junction

Journal of Surgical Oncology

Volumn 110, Issue 3, 2014, Pages 333-340

  Yuan, Dawei ^a   Zhu, Kun ^a   Li, Kang ^a   Yan, Rong ^a   Jia, Yong ^a   Dang, Chengxue ^a  

^a THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

adenocarcinomas of the esophagogastric junction; neutrophil lymphocyte ratio; platelet lymphocyte ratio; recurrence prognosis

Indexed keywords

FLUOROURACIL;

ADJUVANT THERAPY; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; DEMOGRAPHY; DISEASE DURATION; DISEASE FREE SURVIVAL; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMA; ESOPHAGUS RESECTION; FEMALE; FOLLOW UP; GASTRECTOMY; HEMATOLOGICAL PARAMETERS; HISTOPATHOLOGY; HUMAN; LOWER ESOPHAGUS SPHINCTER; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL LYMPHOCYTE RATIO; OVERALL SURVIVAL; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL TIME;

ADENOCARCINOMAS OF THE ESOPHAGOGASTRIC JUNCTION; NEUTROPHIL-LYMPHOCYTE RATIO; PLATELET-LYMPHOCYTE RATIO; RECURRENCE, PROGNOSIS;

ADENOCARCINOMA; ADULT; AGED; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; ESOPHAGOGASTRIC JUNCTION; FEMALE; GASTRECTOMY; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEUTROPHILS; PLATELET COUNT; PREOPERATIVE PERIOD; PROGNOSIS; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS;

EID: 84905499151     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23651     Document Type: Article

References (46)

1. Hasegawa S, Yoshikawa T:, Adenocarcinoma of the esophagogastric junction: incidence, characteristics, and treatment strategies. Gastric Cancer 2010; 13: 63-73.
2. Siewert JR, Feith M, Stein HJ:, Biologic and clinical variations of adenocarcinoma at the esophago-gastric junction: Relevance of a topographic-anatomic subclassification. J Surg Oncol 2005; 90: 139-146.
3. Devesa SS, Blot WJ, Fraumeni JF:, Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998; 83: 2049-2053.
4. Siewert JR, Feith M, Werner M, et al.: Adenocarcinoma of the esophagogastric junction: Results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. Ann Surg 2000; 232: 353.
5. Reynolds JV, Ravi N, Muldoon C, et al.: Differential pathologic variables and outcomes across the spectrum of adenocarcinoma of the esophagogastric junction. World J Surg 2010; 34: 2821-2829.
6. Von Rahden BH, Stein HJ, Feith M, et al.: Lymphatic vessel invasion as a prognostic factor in patients with primary resected adenocarcinomas of the esophagogastric junction. J Clin Oncol 2005; 23: 874-879.
7. Colotta F, Allavena P, Sica A, et al.: Cancer-related inflammation, the seventh hallmark of cancer: Links to genetic instability. Carcinogenesis 2009; 30: 1073-1081.
8. Balkwill F, Mantovani A:, Inflammation and cancer: Back to Virchow ? Lancet 2001; 357: 539-545.
9. Maltoni M, Caraceni A, Brunelli C, et al.: Prognostic factors in advanced cancer patients: Evidence-based clinical recommendations-A study by the Steering Committee of the European Association for Palliative Care. J Clin Oncol 2005; 23: 6240-6248.
10. Epstein FH, Gabay C, Kushner I:, Acute-phase proteins and other systemic responses to inflammation. N Eng J Med 1999; 340: 448-454.
11. McMillan DC, Scott HR, Watson WS, et al.: Longitudinal study of body cell mass depletion and the inflammatory response in cancer patients. Nutrition and Cancer 1998; 31: 101-105.
12. Nozoe T, Saeki H, Sugimachi K:, Significance of preoperative elevation of serum C-reactive protein as an indicator of prognosis in esophageal carcinoma. Am J Surg 2001; 182: 197-201.
13. Shimada H, Nabeya Y, Okazumi SI, et al.: Elevation of preoperative serum C-reactive protein level is related to poor prognosis in esophageal squamous cell carcinoma. J Surg Oncol 2003; 83: 248-252.
14. Crumley A, McMillan D, McKernan M, et al.: An elevated C-reactive protein concentration, prior to surgery, predicts poor cancer-specific survival in patients undergoing resection for gastro-oesophageal cancer. Br J Cancer 2006; 94: 1568-1571.
15. Proctor MJ, Morrison DS, Talwar D, et al.: A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer 2011; 47: 2633-2641.
16. Roxburgh CS, McMillan DC:, Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Fut Oncol 2010; 6: 149-163.
17. Siewert J, Stein H:, Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg 1998; 85: 1457-1459.
18. Edge SB BD, Compton CC, Fritz AG, et al.:, editors. AJCC cancer staging manual (7th ed). New York, NY: Springer; 2010.
19. Sobin LH, Gospodarowicz MK, Wittekind C,. TNM classification of malignant tumours (7th ed). New York, NY: John Wiley & Sons; 2011.
20. Dutta S, Crumley AB, Fullarton GM, et al.: Comparison of the prognostic value of tumour-and patient-related factors in patients undergoing potentially curative resection of oesophageal cancer. World J Surg 2011; 35: 1861-1866.
21. Zhang H, Wang W, Cheng Y, et al.: Adenocarcinomas of the esophagogastric junction: Experiences at a single institution in China. World J Surg Oncol 2013; 11: 155.
22. Bruckner HW, Lavin PT, Plaxe SC, et al.: Absolute granulocyte, lymphocyte, and monocyte counts. JAMA 1982; 247: 1004-1006.
23. Ikeda M, Furukawa H, Imamura H, et al.: Poor prognosis associated with thrombocytosis in patients with gastric cancer. Ann Surg Oncol 2002; 9: 287-291.
24. Ikeda M, Natsugoe S, Ueno S, et al.: Significant host-and tumor-related factors for predicting prognosis in patients with esophageal carcinoma. Ann Surg 2003; 238: 197.
25. Sharaiha RZ, Halazun KJ, Mirza F, et al.: Elevated preoperative neutrophil: Lymphocyte ratio as a predictor of postoperative disease recurrence in esophageal cancer. Ann Surg Oncol 2011; 18: 3362-3369.
26. Hirashima M, Higuchi S, Sakamoto K, et al.: The ratio of neutrophils to lymphocytes and the phenotypes of neutrophils in patients with early gastric cancer. J Cancer Res Clin Oncol 1998; 124: 329-334.
27. Aliustaoglu M, Bilici A, Ustaalioglu BBO, et al.: The effect of peripheral blood values on prognosis of patients with locally advanced gastric cancer before treatment. Med Oncol 2010; 27: 1060-1065.
28. Nozoe T, Ninomiya M, Maeda T, et al.: Prognostic nutritional index: A tool to predict the biological aggressiveness of gastric carcinoma. Surg Today 2010; 40: 440-443.
29. Crumley AB, Stuart RC, McKernan M, et al.: Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG-ps) in patients receiving palliative chemotherapy for gastroesophageal cancer. J Gastroenterol Hepatol 2008; 23: e325-e329.
30. Vashist YK, Loos J, Dedow J, et al.: Glasgow Prognostic Score is a predictor of perioperative and long-term outcome in patients with only surgically treated esophageal cancer. Ann Surg Oncol 2011; 18: 1130-1138.
31. Lord B, Bronchud M, Owens S, et al.: The kinetics of human granulopoiesis following treatment with granulocyte colony-stimulating factor in vivo. Proc Natl Acad Sci USA 1989; 86: 9499-9503.
32. Gregory AD, Houghton AM:, Tumor-associated neutrophils: New targets for cancer therapy. Cancer Res 2011; 71: 2411-2416.
33. Zhao J-j, Pan K, Wang W, et al.: The prognostic value of tumor-infiltrating neutrophils in gastric adenocarcinoma after resection. PloS ONE 2012; 7: e33655.
34. Dunn GP, Old LJ, Schreiber RD:, The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004; 21: 137-148.
35. Lissoni P, Brivio F, Fumagalli L, et al.: Efficacy of cancer chemotherapy in relation to the pretreatment number of lymphocytes in patients with metastatic solid tumors. Int J Biol Markers 2004; 19: 135-140.
36. Walsh S, Cook E, Goulder F, et al.: Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol 2005; 91: 181-184.
37. Sarraf KM, Belcher E, Raevsky E, et al.: Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. J Thorac Cardiovasc Surg 2009; 137: 425-428.
38. Gomez D, Farid S, Malik H, et al.: Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma. World J Surg 2008; 32: 1757-1762.
39. McMillan DC:, Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care 2009; 12: 223-226.
40. Kwon H-C, Kim SH, Oh SY, et al.: Clinical significance of preoperative neutrophil-lymphocyte versus platelet-lymphocyte ratio in patients with operable colorectal cancer. Biomarkers 2012; 17: 216-222.
41. Rashid F, Waraich N, Bhatti I, et al.: A pre-operative elevated neutrophil: Lymphocyte ratio does not predict survival from oesophageal cancer resection. World J Surg Oncol 2010; 8.
42. Noble F, Hopkins J, Curtis N, et al.: The role of systemic inflammatory and nutritional blood-borne markers in predicting response to neoadjuvant chemotherapy and survival in oesophagogastric cancer. Med Oncol 2013; 30: 1-14.
43. Sierko E, Wojtukiewicz MZ:, Platelets and angiogenesis in malignancy. In Seminars in thrombosis and hemostasis, Edition Copyright © 2004 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. 2004; pp. 95-108.
44. Honn KV, Tang DG, Crissman JD:, Platelets and cancer metastasis: A causal relationship ? Cancer Metastasis Rev 1992; 11: 325-351.
45. Shimada H, Oohira G, Okazumi S, et al.: Thrombocytosis associated with poor prognosis in patients with esophageal carcinoma. J Am Coll Surg 2004; 198: 737-741.
46. Smith RA, Bosonnet L, Raraty M, et al.: Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg 2009; 197: 466-472.